| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;101:2071.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Fenfluramine and Phentermine and Cardiovascular Findings
Effect of Treatment Duration on Prevalence of Valve Abnormalities
Presented at the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, La, March 9, 1999.
From the Division of Cardiology (J.G.J., C.K.L., J.K., T.R.), Duke University Medical Center, Durham, NC, and Wyeth-Ayerst Research (G.D.C., K.D.D.), Philadelphia, Pa.
Correspondence to James G. Jollis, MD, Box 3542, Duke University Medical Center, Durham, NC 27710. E-mail james.jollis{at}duke.edu
Background—The combination of fenfluramine and phentermine was a widely used obesity treatment before the withdrawal of fenfluramine for an association with heart valve regurgitation. The prevalence and clinical significance of regurgitation among patients treated with these medications has yet to be fully established.
Methods and Results—To evaluate the potential association between the duration of treatment and the prevalence of heart valve abnormalities, we examined 1163 patients who had taken fenfluramine-phentermine and 672 control patients who had not taken the drug combination within 5 years. Mild or greater aortic regurgitation was present in 8.8% of treated patients and 3.6% of control patients (P<0.001). Moderate or greater mitral regurgitation was present in 2.6% of treated patients and 1.5% of control patients (P=0.18). The adjusted odds ratio compared with controls of aortic regurgitation of mild or greater severity increased according to duration of treatment: 90 to 180 days, 1.5 (P=0.23); 181 to 360 days, 2.4 (P=0.002); 361 to 720 days, 4.6 (P<0.001); >720 days, 6.2 (P<0.001).
Conclusions—This is the largest study to demonstrate a relation between the length of treatment with fenfluramine-phentermine and the prevalence of valvular abnormalities. These findings suggest that valvular abnormalities in patients who took fenfluramine-phentermine primarily involve those who had taken these medications for >6 months and predominantly results in mild aortic regurgitation. The valve regurgitation identified by this study was not accompanied by significant differences in cardiovascular symptoms nor physical findings other than a higher prevalence of heart murmurs.
Key Words: echocardiography • regurgitation • valves • epidemiology
This article has been cited by other articles:
 |
|
 |
|
  S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp Role of echocardiography in toxic heart valvulopathy Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Elangbam REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns Vet. Pathol., January 1, 2009; 46(1): 10 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., September 23, 2008; 52(13): e1 - e142. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kars, V. Delgado, E. R. Holman, R. A. Feelders, J. W. A. Smit, J. A. Romijn, J. J. Bax, and A. M. Pereira Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3348 - 3356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Waller, J. Kaplan, and M. G. Heckman Valvular Heart Disease in Patients Taking Pergolide Mayo Clin. Proc., August 1, 2005; 80(8): 1016 - 1020. [Abstract] [PDF]
|
|
|
|
 |
|
 E. LESSARD, M. GLICK, S. AHMED, and M. SARIC The patient with a heart murmur: Evaluation, assessment and dental considerations J Am Dent Assoc, March 1, 2005; 136(3): 347 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Unger, J. Nortier, M.-C. Muniz Martinez, D. Plein, J.-L. Vandenbossche, P. Vereerstraeten, and J.-L. Vanherweghem High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy Nephrol. Dial. Transplant., May 1, 2003; 18(5): 906 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Califf and D. L. DeMets Principles From Clinical Trials Relevant to Clinical Practice: Part I Circulation, August 20, 2002; 106(8): 1015 - 1021. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Gardin, N. J. Weissman, C. Leung, J. A. Panza, D. Fernicola, K. D. Davis, G. D. Constantine, and C. L. Reid Clinical and Echocardiographic Follow-up of Patients Previously Treated With Dexfenfluramine or Phentermine/Fenfluramine JAMA, October 24, 2001; 286(16): 2011 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Glazer Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety Arch Intern Med, August 13, 2001; 161(15): 1814 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Davidoff, A. McTiernan, G. Constantine, K. D. Davis, G. J. Balady, L. A. Mendes, R. E. Rudolph, and D. J. Bowen Echocardiographic Examination of Women Previously Treated With Fenfluramine: Long-term Follow-up of a Randomized, Double-blind, Placebo-Controlled Trial Arch Intern Med, June 11, 2001; 161(11): 1429 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bierig and A. D. Waggoner Aortic Insufficiency: Etiology, Pathophysiology, Natural History, and the Role of Echocardiography Journal of Diagnostic Medical Sonography, March 1, 2001; 17(2): 59 - 71. [Abstract] [PDF]
|
|
|
|
|
|
R. B. Rothman, M. H. Baumann, J. E. Savage, L. Rauser, A. McBride, S. J. Hufeisen, and B. L. Roth Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications Circulation, December 5, 2000; 102(23): 2836 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Long-Term Use of Fen-Phen Causes Aortic Regurgitation Journal Watch Cardiology, July 14, 2000; 2000(714): 6 - 6. [Full Text]
|
|